Research Topics
| Adrian TowseSummaryAffiliation: Office of Health Economics Country: UK Publications
| Collaborators
|
Detail Information
Publications
If it ain't broke, don't price fix it: the OFT and the PPRSAdrian Towse
Office of Health Economics, London, UK
Health Econ 16:653-65. 2007....- National Institute for Clinical Excellence (NICE): Is economic appraisal working?Adrian Towse
Office of Health Economics, London, UK
Pharmacoeconomics 20:95-105. 2002..NICE should be asked to look at established technologies that may not be cost effective and whose discontinuance could therefore release resources for other more cost-effective treatments... - Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?Adrian Towse
Office of Health Economics, 12 Whitehall, London, UK
Br J Clin Pharmacol 70:360-6. 2010..Enabling the NHS to deliver on such schemes will impact favourably on R&D decisions. Increasing the uncertainty in the UK NHS market through government price setting will reduce incentives for R&D and for early UK launch... - Learning from Thailand's health reformsAdrian Towse
Office of Health Economics, London SW1A 2DY
BMJ 328:103-5. 2004 - Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical productsAdrian Towse
Office of Health Economics, London, UK
Pharmacoeconomics 28:93-102. 2010..Given the lack of empirical evidence on the success of schemes already agreed and on the issues we set out above, it is too early to tell if the recent surge of interest in these arrangements is likely to be a trend or only a fad... - Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policiesAdrian Towse
Office of Health Economics, London, England
Bull World Health Organ 83:301-7. 2005..Our key conclusion is that that APPCs have the potential to be a powerful tool and should be tried. The correct structure and design may only be determined through the process of taking action to set one up... - The drug budget silo mentality in Europe: an overviewLou Garrison
Health Economics and Strategic Pricing, Roche Pharmaceuticals, Basel, Switzerland; Office of Health Economics, London, UK
Value Health 6:S1-9. 2003 - The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit?Adrian Towse
Office of Health Economics, London
Health Aff (Millwood) 22:42-5. 2003..In the end, silo-based budgeting is short-sighted; the emphasis in Europe and in the United States should be on measures that achieve efficient health care rather than the containment of drug spending... - Using QALYs in cancer: a review of the methodological limitationsMartina Garau
Office of Health Economics, London, UK
Pharmacoeconomics 29:673-85. 2011..A research agenda for addressing these limitations is proposed... - Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizabilityMarco Barbieri
Innovus Research (UK) Ltd. High Wycombe, UK
Value Health 8:10-23. 2005..The lessons for inferring generalizability are not straightforward, although the implications of variation for decision making depend critically on the cost-effectiveness thresholds applying in Western Europe... - Making amends for negligencePaul Fenn
BMJ 328:417-8. 2004 - Differential pricing for pharmaceuticals: reconciling access, R&D and patentsPatricia M Danzon
Wharton School, University of Pennsylvania, USA
Int J Health Care Finance Econ 3:183-205. 2003..Differential pricing could go a long way to improve LDC access to drugs that have a high income market. However, other subsidy mechanisms will be needed to promote R&D for drugs that have no high income market... - The economics of gene therapy and of pharmacogeneticsPatricia Danzon
Wharton School, University of Pennsylvania, Philadelphia, PA, USA
Value Health 5:5-13. 2002..This problem with small numbers is analogous to that associated with gene therapy for monogenic diseases and may require similar remedies if society values developing treatments for these diseases... - The desirability and feasibility of economic studies of drugs post-launchMichael Drummond
Eur J Health Econ 7:5-6. 2006 - Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysisLouis P Garrison
Department of Pharmacy, University of Washington, Seattle, USA
Health Aff (Millwood) 26:684-95. 2007.... - Influencing prescribing in English primary care: the views of primary care organisationsAnne Mason
Centre for Health Economics, University of York, York, UK
J Health Serv Res Policy 9:153-8. 2004....